Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04553406 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
A Phase 2 study, sponsored by Spero Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04553406 is a Phase 2 study that was terminated before completion, run by Spero Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT04553406, a Phase 2 study, was terminated before completion, sponsored by Spero Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
Interventions
- DRUG Placebo
- DRUG SPR720
- DRUG Open-label Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-12-03 |
| Est. Completion | 2021-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04553406
The ClinicalTrials.gov registry entry for NCT04553406 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spero Therapeutics, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04553406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04553406 about?
NCT04553406 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease". To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
What is the current status of trial NCT04553406?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-12-03. Estimated completion is 2021-01-28.
What interventions are being tested in trial NCT04553406?
The interventions under investigation include: Placebo (DRUG), SPR720 (DRUG), Open-label Standard of Care (DRUG).
Who is sponsoring clinical trial NCT04553406?
This trial is sponsored by Spero Therapeutics, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.